Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer [Phase 3]
Phase 3 trial assessing reduced-dose pegfilgrastim as support for chemotherapy in breast cancer.
-
CLINICAL_TRIALS research · 2024-03-18Clinical Trial Update: Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk
Clinical trial update examining barriers to screening breast MRI utilization among patients at elevated risk; completed with results posted …
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid [Phase 3]
Phase 3 trial comparing tamoxifen to anastrozole, alone or with zoledronic acid in breast cancer; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy [Phase 3]
Phase 3 clinical trial evaluating capecitabine plus camrelizumab for non-pCR triple-negative breast cancer with tumor-infiltrating lymphocyt…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients" [Phase 2]
Phase 2 clinical trial evaluating adding pentoxifylline to neoadjuvant chemotherapy in breast cancer patients; status is currently unknown.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies [Phase 2]
Phase 2 trial of poziotinib in EGFR or HER2 activating mutations across advanced malignancies was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer [Phase 3]
A Phase 3 trial evaluating nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy versus placebo in high-risk ER-positive, H…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer [Phase 2]
Phase 2 trial update for trilaciclib in early-stage triple-negative breast cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating ipatasertib plus paclitaxel in PI3K/AKT/PTEN-altered locally advanced or metastatic triple-negative breast cancer o…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) [Phase 3]
Phase 3 clinical trial evaluating dalpiciclib with endocrine therapy for advanced breast cancer after failure of CDK4/6 inhibitors is curren…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy [NA]
Clinical trial update on supine MRI in breast cancer patients undergoing upfront surgery or neoadjuvant therapy; study completed with result…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block [Phase 4]
Phase 4 trial comparing dexamethasone versus dexmedetomidine as adjuncts to serratus anterior plane block for breast cancer treatment contex…
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A safety and tolerability study of NC318 in advanced or metastatic solid tumors completed Phase 1/2 with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Phase II Study of GTx024 in Women With Metastatic Breast Cancer [Phase 2]
Phase II study of GTx024 in women with metastatic breast cancer was terminated; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer [Phase 2]
Phase 2 trial update evaluating combination chemotherapy with trastuzumab in metastatic breast cancer.
-
FDA approval · 2024-03-07FDA Approved: TALZENNA — Original Application (U.S. Pharmaceuticals)
FDA approves TALZENNA (talazoparib) in the original application for the treatment of adult patients with germline BRCA-mutated, HER2-negativ…
-
CLINICAL_TRIALS trial_result · 2024-03-07Clinical Trial Update: Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer [Phase 3]
Phase 3 trial update evaluating neoadjuvant nab-paclitaxel in HER2-negative high-risk breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-03-07Clinical Trial Update: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. [Phase 2]
Phase 2 trial update for MCLA-128 in combination with trastuzumab/chemotherapy in HER2-positive breast cancer and with endocrine therapy in …
-
CLINICAL_TRIALS trial_result · 2024-03-07Clinical Trial Update: Sorafenib in Treating Patients With Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial of sorafenib in metastatic breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer [Phase 2]
Phase II trial evaluating pembrolizumab in combination with nab-paclitaxel for HER-2 negative metastatic breast cancer; results have been po…
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 [Phase 3]
Phase 3 neoadjuvant trial update in triple-negative breast cancer evaluating anti-PD-L1 therapy combined with standard treatment.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System [NA]
A completed clinical trial update assessing care coordination for complex cancer survivors within an integrated safety net system; results p…
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage [Phase 4]
Phase 4 trial assessing Hemopatch® effectiveness in reducing post-surgical serous drainage in breast cancer patients undergoing axillary lym…
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer [Phase 3]
Phase 3 neoadjuvant trial update for HER2-positive early high-risk and locally advanced breast cancer.
-
FDA approval · 2024-03-05FDA Approved: CAPECITABINE — Original Application (BluePoint Laboratories)
The FDA approved the original application for capecitabine by BluePoint Laboratories, enabling a generic version of the cancer drug.